183 related articles for article (PubMed ID: 38670950)
1. Cas13d-mediated gene knockdown in CAR T cells: towards off-the-shelf cancer treatment.
Johnston M; Urban N; Dincer C
Signal Transduct Target Ther; 2024 Apr; 9(1):113. PubMed ID: 38670950
[No Abstract] [Full Text] [Related]
2. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
Morgan MA; Büning H; Sauer M; Schambach A
Front Immunol; 2020; 11():1965. PubMed ID: 32903482
[TBL] [Abstract][Full Text] [Related]
3. Advances in off-the-shelf CAR T-cell therapy.
Benjamin R
Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
[No Abstract] [Full Text] [Related]
4. CAR T-cell therapy for solid tumours.
The Lancet Oncology
Lancet Oncol; 2021 Jul; 22(7):893. PubMed ID: 34197740
[No Abstract] [Full Text] [Related]
5. Tuning the performance of CAR T cell immunotherapies.
Richardson NH; Luttrell JB; Bryant JS; Chamberlain D; Khawaja S; Neeli I; Radic M
BMC Biotechnol; 2019 Nov; 19(1):84. PubMed ID: 31783836
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
Han C; Kwon BS
Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cells profiling in carcinogenesis and tumorigenesis: An overview of CAR T-cells cancer therapy.
Samadani AA; Keymoradzdeh A; Shams S; Soleymanpour A; Rashidy-Pour A; Hashemian H; Vahidi S; Norollahi SE
Int Immunopharmacol; 2021 Jan; 90():107201. PubMed ID: 33249047
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?
Salmikangas P; Kinsella N; Chamberlain P
Pharm Res; 2018 May; 35(8):152. PubMed ID: 29855723
[TBL] [Abstract][Full Text] [Related]
9. CAR T cells for solid tumors - developments to watch in 2023.
Trefny MP; Kobold S
Expert Opin Biol Ther; 2024 Apr; 24(4):207-211. PubMed ID: 38526025
[No Abstract] [Full Text] [Related]
10. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
12. CAR T cells: continuation in a revolution of immunotherapy.
Singh AK; McGuirk JP
Lancet Oncol; 2020 Mar; 21(3):e168-e178. PubMed ID: 32135120
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Pagel JM; West HJ
JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
[No Abstract] [Full Text] [Related]
14. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
Front Immunol; 2021; 12():799206. PubMed ID: 34975912
[TBL] [Abstract][Full Text] [Related]
15. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
16. Imaging of CAR T-Cells in Cancer Patients: Paving the Way to Treatment Monitoring and Outcome Prediction.
Krebs S; Ponomarev V; Slovin S; Schöder H
J Nucl Med; 2019 Jul; 60(7):879-881. PubMed ID: 31053682
[No Abstract] [Full Text] [Related]
17. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
Han X; Wang Y; Wei J; Han W
J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
[TBL] [Abstract][Full Text] [Related]
18. Standardizing CAR-T therapy: Getting it scaled up.
Dai X; Mei Y; Cai D; Han W
Biotechnol Adv; 2019; 37(1):239-245. PubMed ID: 30543841
[TBL] [Abstract][Full Text] [Related]
19. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.
Feucht J; Abou-El-Enein M
Mol Ther; 2020 Oct; 28(10):2108-2110. PubMed ID: 32841587
[No Abstract] [Full Text] [Related]
20. A novel chimeric antigen receptor redirecting T-cell specificity towards CD26
Zhou S; Li W; Xiao Y; Zhu X; Zhong Z; Li Q; Cheng F; Zou P; You Y; Zhu X
Leukemia; 2021 Jan; 35(1):119-129. PubMed ID: 32317776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]